EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Patient-reported outcomes from ASCENT-03: sacituzumab govitecan vs chemotherapy in advanced triple-negative breast cancer

Kevin Punie, Sara M Tolaney, Sara A Hurvitz, Carlos Barrios, Andreas Schneeweiss, Joohyuk Sohn, Eriko Tokunaga, Adam Brufsky, Yeon Hee Park, Binghe Xu, Roberto Hegg, Mafalda Oliveira, Alessandra Fabi, Yuanhui Zhang, Hao Wang, Yutian Mu, Rosemary Delaney, Javier Cortés

The Oncologist · 2026-11-12

DOI: 10.1093/oncolo/oyag448 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background In the ASCENT-03 study, first-line sacituzumab govitecan (SG) led to a statistically significant progression-free survival improvement vs chemotherapy in participants with metastatic triple-negative breast cancer (mTNBC) who were not candidates for PD-(L)1 inhibitors. We report patient-reported outcomes from ASCENT-03. Methods 558 participants were randomized 1:1 to SG or chemotherapy. Participants completed the EORTC QLQ-C30, EORTC QLQ-BR23, EQ-5D-5L, and FACT-GP5 questionnaires. Key secondary endpoints were change from baseline (CFB) at week 25 in physical functioning and time-to-first-meaningful deterioration (TTD) in fatigue. Additional exploratory analyses were performed for other EORTC QLQ-C30 domains and other questionnaires. Results Least-squares mean CFB at week 25 favored SG for physical functioning (difference, 6.89; 95% CI, 3.50-10.28); TTD in fatigue was similar between treatment groups (hazard ratio, 0.98; 95% CI, 0.80-1.19). Least-squares mean CFB also favored SG for role functioning, global health status/quality of life (QOL), fatigue, pain, and dyspnea and favored chemotherapy for diarrhea. TTD favored SG for dyspnea and chemotherapy for nausea/vomiting and diarrhea. Time-to-first-meaningful improvement favored SG for physical, role, cognitive, and social functioning; fatigue; insomnia; appetite loss; and constipation. Other patient-reported outcomes consistently favored SG. Conclusions SG provided meaningful and sustained benefits in QOL vs chemotherapy. Although SG is associated with known increased gastrointestinal side effects, they can be managed and did not adversely affect functioning, long-term QOL, or treatment tolerability. These data complement previous efficacy results and support first-line SG as a new standard of care for patients with mTNBC who are not candidates for PD-(L)1 inhibitors. (ClinicalTrials.gov number, NCT05382299)

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →